# A Study of IBI363 in Subjects With Advanced Malignancies

> **NCT06468098** · PHASE1 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 556 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** IBI363 + chemotherapy
- **DRUG:** IBI363 + Investigator's Choice SOC

## Key facts

- **NCT ID:** NCT06468098
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-15
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 556 (ESTIMATED)
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06468098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06468098, "A Study of IBI363 in Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06468098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*